ClinicalTrials.gg

Thrombocythemia, Essential clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 229 studies for Thrombocythemia, Essential across more than 10 countries. 38 are recruiting or about to start. 49 of them are mainly about Thrombocythemia, Essential (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
131
Recruiting
34
Terminated
25
Active, not recruiting
20
Status unknown
8
Withdrawn
7

Phase

Phase 2
88
Phase 1
68
Phase 3
31
Phase 4
3
Early Phase 1
2

Where

United States
149
Italy
38
France
37
United Kingdom
29
Germany
28
Canada
20

Who develops what

Add Thrombocythemia, Essential to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 4 companies, 3 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
anagrelideRecent, limited
Evidence
  • NCT06079879 · Merck & Co., Inc · Phase 3 · live · comparator · “Anagrelide” · registered Oct 2023
  • NCT04285086 · PharmaEssentia · Phase 3 · live · comparator · “Anagrelide” · registered Feb 2020
  • NCT03123588 · Incyte Corporation · Phase 2 · comparator · “Anagrelide” · registered Apr 2017
  • NCT02076815 · AOP Orphan Pharmaceuticals AG · Phase 3 · comparator · “Thromboreductin” · registered Feb 2014
Takeda67% of its industry studiesUS: off-patent, 2 generics marketedEU: off-patent, 1 generic authorized11 study
ruxolitinibRecent, limited
Evidence
  • NCT06079879 · Merck & Co., Inc · Phase 3 · live · comparator · “Ruxolitinib” · registered Oct 2023
  • NCT02158858 · Constellation Pharmaceuticals · Phase 2 · background · “Ruxolitinib” · registered Jun 2014
  • NCT01787552 · Novartis · Phase 2 · background · “INC424” · registered Feb 2013
Incyte Corporation72% of its industry studiesUS: Incyte Corporation (FDA 2011)EU: Novartis (EMA 2012) + 1 other11 study
HydroxyureaRecent, limited
Evidence
  • NCT06456346 · Merck & Co., Inc · Phase 3 · live · comparator · “Hydroxyurea” · registered Jun 2024
  • NCT01065038 · AOP Orphan Pharmaceuticals AG · Phase 3 · comparator · “Hydroxyurea” · registered Feb 2010
  • NCT00202644 · Takeda · Phase 4 · comparator · “Hydroxyurea” · registered Sep 2005
Norgine33% of its industry studiesUS: off-patent, 5 generics marketedEU: Norgine (EMA 2007) + 1 other11 study

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Anti-mutant Calreticulin Monoclonal Antibody INCA033989☆ Track1 live phase-3 study: NCT07623200Incyte Corporation

The 1 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Thrombocythemia, Essential studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 3 open · Tyrosine kinase inhibitors (TKIs) 3 open · JAK inhibitors 3 open · Alkylating agents 1 open · PARP inhibitors 1 open

Coming up

21studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger. 5 (15%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (6%) take healthy volunteers.

Recruiting studies that take each age, of 34
AgeWomenMen
104 (12%)4 (12%)
1833 (97%)33 (97%)
3032 (94%)32 (94%)
4032 (94%)32 (94%)
5032 (94%)32 (94%)
6531 (91%)31 (91%)
7531 (91%)31 (91%)
8531 (91%)31 (91%)

Across all 229 studies, recruiting or not: 19% stop at 75 or younger and 11% at 65; 24% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Thrombocythemia, Essential studies take

Of 27 phase 2 interventional studies under Thrombocythemia, Essential, half reached primary completion within 64 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 264 mo32–141 · 27 studies——
Observational35 mo26–75 · 15 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 229. Browse all 229 → or search them.